Research Article

Department of Laboratory Medicine, Dalian Medical University, Dalian, PR China

^‡Authors contributed equally

Search for more papers by this author

Hui Chen^‡

Geriatric Medicine, Clinical Medical College of Yangzhou University, Yangzhou, PR China

^‡Authors contributed equally

Search for more papers by this author

Zhanjun Yang

School of Chemistry & Chemical Engineering, Yangzhou University, Yangzhou, PR China

Search for more papers by this author

Chongxu Han

Department of Laboratory Medicine, Clinical Medical College of Yangzhou University, Yangzhou, PR China

Search for more papers by this author

Chuanli Ren

*Author for correspondence: Tel.: +86 0514 8737 3635; Fax: +86 0154 8737 3630;

E-mail Address: renchl@163.com

https://orcid.org/0000-0002-8386-3586

Department of Laboratory Medicine, Clinical Medical College of Yangzhou University, Yangzhou, PR China

Department of Laboratory Medicine, Yangzhou Clinical Medical College of Xuzhou Medical University, Yangzhou, PR China

Search for more papers by this author

Published Online:14 Apr 2020https://doi.org/10.2217/fon-2019-0728

View article

Abstract

Aim: To predict the occurrence of bone metastases and prognosis among patients with gastric cancer on a population level. Materials & methods: Data were obtained from the SEER database (2010–2016). Multivariable logistic regression and multivariable Cox regression were used to determine factors that predict the occurrence of bone metastasis and prognosis. Results: Cardia cancer, younger age, white race, poor differentiation grade, higher N stage, diffuse-type were positively associated with the presence of bone metastasis. For gastric cancer patients with bone metastasis, the median survival time was longer (9.0 months) among patients with surgery of primary site compared with those without surgery (3.0 months). Conclusion: According to the results of risk assessment, clinical efforts should be targeted to focus on screening high-risk patients.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
MedlineGoogle Scholar
2. Riihimaki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget 7(32), 52307–52316 (2016).
MedlineGoogle Scholar
3. Nakamura K, Tomioku M, Nabeshima K, Yasuda S. Clinicopathologic features and clinical outcomes of gastric cancer patients with bone metastasis. Tokai J. Exp. Clin. Med. 39(4), 193–198 (2014).
MedlineGoogle Scholar
4. Mikami J, Kimura Y, Makari Y et al. Clinical outcomes and prognostic factors for gastric cancer patients with bone metastasis. World J. Surg. Oncol. 15(1), 8 (2017).
MedlineGoogle Scholar
5. Kobayashi M, Okabayashi T, Sano T, Araki K. Metastatic bone cancer as a recurrence of early gastric cancer – characteristics and possible mechanisms. World J. Gastroenterol. 11(36), 5587–5591 (2005). • It shows the underestimated incidence and possible mechanisms of gastric cancer patients with bone metastasis, which indicates the purpose of our study.
MedlineGoogle Scholar
6. Ribatti D, Mangialardi G, Vacca A. Stephen Paget and the ‘seed and soil’ theory of metastatic dissemination. Clin. Exp. Med. 6(4), 145–149 (2006).
Medline CASGoogle Scholar
7. Gdowski AS, Ranjan A, Vishwanatha JK. Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J. Exp. Clin. Cancer Res. 36(1), 108–108 (2017).
MedlineGoogle Scholar
8. Tofe AJ, Francis MD, Harvey WJ. Correlation of neoplasms with incidence and localization of skeletal metastases: an analysis of 1,355 diphosphonate bone scans. J. Nucl. Med. 16(11), 986–989 (1975).
Medline CASGoogle Scholar
9. Park HS, Rha SY, Kim HS et al. A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis. Oncology 80(1–2), 142–150 (2011).
MedlineGoogle Scholar
10. Ahn JB, Ha TK, Kwon SJ. Bone metastasis in gastric cancer patients. J. Gastric Cancer 11(1), 38–45 (2011).
MedlineGoogle Scholar
11. Clezardin P. Pathophysiology of bone metastases from solid malignancies. Joint Bone Spine 84(6), 677–684 (2017).
Medline CASGoogle Scholar
12. Turkoz FP, Solak M, Kilickap S et al. Bone metastasis from gastric cancer: the incidence, clinicopathological features and influence on survival. J. Gastric Cancer 14(3), 164–172 (2014).
MedlineGoogle Scholar
13. Qiu MZ, Shi SM, Chen ZH et al. Frequency and clinicopathological features of metastasis to liver, lung, bone and brain from gastric cancer: a SEER-based study. Cancer Med. 7(8), 3662–3672 (2018).
MedlineGoogle Scholar
14. Nishidoi H, Koga S. [Clinicopathological study of gastric cancer with bone metastasis]. Gan To Kagaku Ryoho 14(5 Pt 2), 1717–1722 (1987).
Medline CASGoogle Scholar
15. Yoshikawa K, Kitaoka H. Bone metastasis of gastric cancer. Jpn J. Surg. 13(3), 173–176 (1983).
Medline CASGoogle Scholar
16. Kim HS, Yi SY, Jun HJ et al. Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology 73(3–4), 192–197 (2007).
MedlineGoogle Scholar
17. Ramos-De la Medina A, Salgado-Nesme N, Torres-Villalobos G, Medina-Franco H. Clinicopathologic characteristics of gastric cancer in a young patient population. J. Gastrointest. Surg. 8(3), 240–244 (2004).
MedlineGoogle Scholar
18. Kim MA, Lee HS, Yang HK, Kim WH. Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer 103(7), 1439–1446 (2005). • Indicates that cardiac cancer is prone to metastasis at the gene level.
MedlineGoogle Scholar
19. Ribeiro MM, Sarmento JA, Sobrinho Simoes MA, Bastos J. Prognostic significance of Lauren and Ming classifications and other pathologic parameters in gastric carcinoma. Cancer 47(4), 780–784 (1981).
Medline CASGoogle Scholar
20. Adachi Y, Yasuda K, Inomata M et al. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer 89(7), 1418–1424 (2000).
Medline CASGoogle Scholar
21. Lee T, Tanaka H, Ohira M et al. Clinical impact of the extent of lymph node micrometastasis in undifferentiated-type early gastric cancer. Oncology 86(4), 244–252 (2014).
MedlineGoogle Scholar
22. Sano T, Coit DG, Kim HH et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer 20(2), 217–225 (2017).
MedlineGoogle Scholar
23. Pang L, Wang J, Fan Y et al. Correlations of TNM staging and lymph node metastasis of gastric cancer with MRI features and VEGF expression. Cancer Biomark. 23(1), 53–59 (2018).
Medline CASGoogle Scholar
24. Guo X, Zhang C, Guo Q et al. The homogeneous and heterogeneous risk factors for the morbidity and prognosis of bone metastasis in patients with prostate cancer. Cancer Manag. Res. 10, 1639–1646 (2018).
MedlineGoogle Scholar
25. Zhang Y, Guo X, Wang G et al. Real-world study of the incidence, risk factors and prognostic factors associated with bone metastases in women with uterine cervical cancer using Surveillance, Epidemiology and End Results (SEER) data analysis. Med. Sci. Monit. 24, 6387–6397 (2018).
MedlineGoogle Scholar
26. Guo X, Zhang C, Ma W et al. Patterns of bone metastases in newly diagnosed colorectal cancer: a real-world analysis in the SEER database. Int. J. Colorectal Dis. 34(3), 533–543 (2019).
MedlineGoogle Scholar
27. Makino T, Fujiwara Y, Takiguchi S et al. Preoperative T staging of gastric cancer by multi-detector row computed tomography. Surgery 149(5), 672–679 (2011).
MedlineGoogle Scholar
28. Prado Wohlwend S, Sanchez Vano R, Sopena Novales P et al. Gastric cancer bone metastases together with osteopoikilosis diagnosed using bone scintigraphy and (18)F-FDG PET/CT. Revista espanola de medicina nuclear e imagen molecular 36(3), 189–193 (2017).
MedlineGoogle Scholar
29. Kawanaka Y, Kitajima K, Fukushima K et al. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: comparison with contrast-enhanced MDCT. Eur. J. Radiol. 85(5), 989–995 (2016).
MedlineGoogle Scholar
30. Zhou M, Wang C, Hu S et al. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging. Nucl. Med. Commun. 34(7), 694–700 (2013).
Medline CASGoogle Scholar
31. Sollini M, Calabrese L, Zangheri B et al. (18)F-FDG PET/CT versus bone scintigraphy in the follow-up of gastric cancer. Revista espanola de medicina nuclear e imagen molecular 35(2), 121–123 (2016).
Medline CASGoogle Scholar
32. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br. J. Surg. 85(11), 1457–1459 (1998).
Medline CASGoogle Scholar
33. Amini N, Spolverato G, Kim Y, Squires MH, Poultsides GA, Fields R et al. Clinicopathological features and prognosis of gastric cardia adenocarcinoma: a multi-institutional US study. J. Surg. Oncol. 111(3), 285–292 (2015).
MedlineGoogle Scholar
34. Deans C, Yeo MSW, Soe MY, Shabbir A, Ti TK, So JBY. Cancer of the gastric cardia is rising in incidence in an Asian population and is associated with adverse outcome. World J. Surg. 35(3), 617–624 (2011).
MedlineGoogle Scholar
35. Saito H, Fukumoto Y, Osaki T et al. Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach. World J. Surg. 30(10), 1864–1869 (2006).
MedlineGoogle Scholar
36. Deans C, Yeo MS, Soe MY et al. Cancer of the gastric cardia is rising in incidence in an Asian population and is associated with adverse outcome. World J. Surg. 35(3), 617–624 (2011).
MedlineGoogle Scholar
37. Ohno S, Tomisaki S, Oiwa H et al. Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach. J. Am. Coll. Surg. 180(5), 577–582 (1995).
Medline CASGoogle Scholar
38. Kim JG, Ryoo BY, Park YH et al. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother. Pharmacol. 61(2), 301–307 (2008).
Medline CASGoogle Scholar
39. Song Z, Wu Y, Yang J, Yang D, Fang X. Progress in the treatment of advanced gastric cancer. Tumour Biol. 39(7), 1010428317714626 (2017).
Google Scholar
40. Sun J, Song Y, Wang Z et al. Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC cancer 13, 577 (2013).
Medline CASGoogle Scholar
41. Hartgrink HH, Putter H, Klein Kranenbarg E, Bonenkamp JJ, van de Velde CJ. Value of palliative resection in gastric cancer. Br. J. Surg. 89(11), 1438–1443 (2002).
Medline CASGoogle Scholar
42. Kim KH, Lee KW, Baek SK et al. Survival benefit of gastrectomy +/− metastasectomy in patients with metastatic gastric cancer receiving chemotherapy. Gastric Cancer 14(2), 130–138 (2011).
MedlineGoogle Scholar
43. Japan Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 20(1), 1–19 (2017).
Google Scholar
44. Ajani JA, D'Amico TA, Almhanna K et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 14(10), 1286–1312 (2016). •• Our results verify the treatment methods advocated by the guidelines and provide the clinical evidence for the development of the guidelines.
MedlineGoogle Scholar
45. Ichikawa W, Sasaki Y. Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients. Ann. Oncol. 17(11), 1665–1672 (2006).
Medline CASGoogle Scholar
46. Shitara K, Matsuo K, Muro K, Doi T, Ohtsu A. Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer. Gastric Cancer 17(2), 362–370 (2014).
Medline CASGoogle Scholar
47. Shridhar R, Almhanna K, Hoffe SE et al. Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a Surveillance, Epidemiology and End Results database analysis. Cancer 119(9), 1636–1642 (2013).
MedlineGoogle Scholar

Vol. 16, No. 12

Metrics

Downloaded 183 times

History

Received 9 November 2019

Accepted 12 March 2020

Published online 14 April 2020

Published in print April 2020

Information

Keywords

Author contributions

C Liang had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design was performed by C Han; manuscript drafting and reviewing was performed by C Ren; acquisition, analysis and interpretation of data were performed by all authors; statistical analysis was performed by C Liang; administrative, technical and material support was given by H Chen. C Liang and H Chen contributed equally to this work.

Financial & competing interests disclosure

This study was supported by the National Natural Science Foundation of China (81573220) and the Foundation for Young Medical Scholars in Jiangsu Province (QNRC2016325 and QNRC2016333). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Data sharing statement

The authors certify that the secondary analysis of clinical trial data that have been shared with them. The source of this data is: the SEER database-18 cohort database (Incidence – SEER 18 Regs Research Data and Hurricane Katrina Impacted Louisiana Cases, November 2018 Sub [1973–2016 varying]), released in November 2018.

PDF download

Risk factors and prognosis of bone metastases in newly diagnosed gastric cancer

Abstract

References